<?xml version='1.0' encoding='utf-8'?>
<document id="20840444"><sentence text="Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials."><entity charOffset="0-11" id="DDI-PubMed.20840444.s1.e0" text="Desipramine" /></sentence><sentence text="To develop a population pharmacokinetic model to describe the pharmacokinetics of desipramine in healthy subjects, after oral administration of a 50mg dose"><entity charOffset="82-93" id="DDI-PubMed.20840444.s2.e0" text="desipramine" /></sentence><sentence text=" Additional objectives were to develop a semi-mechanistic population pharmacokinetic model for desipramine, which allowed simulation of CYP2D6-mediated inhibition, when using desipramine as a probe substrate, and to evaluate certain study design elements, such as duration of desipramine pharmacokinetic sampling, required sample size and optimal pharmacokinetic sampling schedule for intermediate, extensive and ultrarapid metabolizers of CYP2D6 substrates"><entity charOffset="95-106" id="DDI-PubMed.20840444.s3.e0" text="desipramine" /><entity charOffset="175-186" id="DDI-PubMed.20840444.s3.e1" text="desipramine" /><entity charOffset="276-287" id="DDI-PubMed.20840444.s3.e2" text="desipramine" /><pair ddi="false" e1="DDI-PubMed.20840444.s3.e0" e2="DDI-PubMed.20840444.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20840444.s3.e0" e2="DDI-PubMed.20840444.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20840444.s3.e0" e2="DDI-PubMed.20840444.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20840444.s3.e1" e2="DDI-PubMed.20840444.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20840444.s3.e1" e2="DDI-PubMed.20840444.s3.e2" /></sentence><sentence text="" /><sentence text="The mean population estimates of the first order absorption rate constant (k(a) ), apparent clearance (CL/F) and apparent volume of distribution at steady state (V(ss) /F) were 0" /><sentence text="15h(-1) , 111 lh(-1) and 2950 l, respectively" /><sentence text=" Further, using the proposed semi-mechanistic hepatic intrinsic clearance model with Bayesian inference, mean population desipramine hepatic intrinsic clearance was estimated to be 262 lh(-1) with between-subject variability of 84%"><entity charOffset="121-132" id="DDI-PubMed.20840444.s7.e0" text="desipramine" /></sentence><sentence text=" d-optimal PK sampling times for intermediate metabolizers were calculated to be approximately 0" /><sentence text="25, 24, 75 and 200h" /><sentence text=" Similar sampling times were found for ultrarapid and extensive metabolizers except that the second d-optimal sample was earlier at 14 and 19h, respectively, compared with 24h for intermediate metabolizers" /><sentence text=" This difference in sampling times between the three genotypes can be attributed to the different intrinsic clearances and elimination rates" /><sentence text="" /><sentence text="A two compartment population pharmacokinetic model best described desipramine disposition"><entity charOffset="66-77" id="DDI-PubMed.20840444.s13.e0" text="desipramine" /></sentence><sentence text=" The semi-mechanistic population model developed is suitable to describe the pharmacokinetic behaviour of desipramine for the dose routinely used in drug-drug interaction (DDI) studies"><entity charOffset="106-117" id="DDI-PubMed.20840444.s14.e0" text="desipramine" /></sentence><sentence text=" Based on this meta-analysis of seven trials, a sample size of 21 subjects in cross-over design is appropriate for assessing CYP2D6 interaction with novel compounds" /><sentence text="" /></document>